Compounds > levofloxacin
Page last updated: 2024-09-04

levofloxacin and pentamidine

levofloxacin has been researched along with pentamidine in 7 studies

Compound Research Comparison

Studies
(levofloxacin)		Trials
(levofloxacin)		Recent Studies (post-2010)
(levofloxacin)		Studies
(pentamidine)		Trials
(pentamidine)		Recent Studies (post-2010) (pentamidine)
4,3465812,2092,411136477

Protein Interaction Comparison

ProteinTaxonomylevofloxacin (IC50)pentamidine (IC50)
Solute carrier family 22 member 2Homo sapiens (human)1.2
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)3.278
Protein tyrosine phosphatase type IVA 3Homo sapiens (human)0.3
Solute carrier family 22 member 3Homo sapiens (human)9.5
PlasminogenHomo sapiens (human)7.3333
Urokinase-type plasminogen activatorHomo sapiens (human)10
Trypsin-1Homo sapiens (human)10
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)2.214
Muscarinic acetylcholine receptor M2Homo sapiens (human)1.425
Muscarinic acetylcholine receptor M4Homo sapiens (human)1.58
Muscarinic acetylcholine receptor M5Homo sapiens (human)2.885
Alpha-2A adrenergic receptorHomo sapiens (human)1.375
Cytochrome P450 2D6Homo sapiens (human)10
Amine oxidase [flavin-containing] AHomo sapiens (human)0.793
Sodium-dependent noradrenaline transporter Homo sapiens (human)2.214
5-hydroxytryptamine receptor 2AHomo sapiens (human)1.639
5-hydroxytryptamine receptor 2CHomo sapiens (human)3.278
D(3) dopamine receptorHomo sapiens (human)3.998
Sodium-dependent dopamine transporter Homo sapiens (human)3.159
Glutamate receptor ionotropic, NMDA 1Homo sapiens (human)0.72
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)10
Glutamate receptor ionotropic, NMDA 2AHomo sapiens (human)0.72
Protein tyrosine phosphatase type IVA 2Homo sapiens (human)0.3
Multidrug and toxin extrusion protein 2Homo sapiens (human)2.7
Protein tyrosine phosphatase type IVA 1Homo sapiens (human)0.3
Multidrug and toxin extrusion protein 1Homo sapiens (human)1.7033

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's5 (71.43)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Lombardo, F; Obach, RS; Waters, NJ1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Ashenden, S; Bender, A; Cokol, M; Karakoc, I; Kuru, N; Mason, DJ; Meral, S; Stott, I; Weinstein, ZB1

Reviews

1 review(s) available for levofloxacin and pentamidine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

6 other study(ies) available for levofloxacin and pentamidine

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
    Journal of medicinal chemistry, 2013, Feb-14, Volume: 56, Issue:3

    Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs

2013
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure.
    Journal of medicinal chemistry, 2017, 05-11, Volume: 60, Issue:9

    Topics: Anti-Bacterial Agents; Drug Interactions; Molecular Structure

2017